Haven Capital Group Inc. Makes New $3.87 Million Investment in Edwards Lifesciences Co. (NYSE:EW)

Haven Capital Group Inc. bought a new position in Edwards Lifesciences Co. (NYSE:EW) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 52,279 shares of the medical research company’s stock, valued at approximately $3,870,000. Edwards Lifesciences accounts for about 3.6% of Haven Capital Group Inc.’s investment portfolio, making the stock its 10th largest position.

A number of other large investors have also added to or reduced their stakes in the stock. Abacus Planning Group Inc. grew its position in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after acquiring an additional 140 shares during the period. Bowman & Co S.C. increased its stake in Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after buying an additional 148 shares in the last quarter. Moors & Cabot Inc. increased its stake in Edwards Lifesciences by 0.3% in the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock worth $4,041,000 after buying an additional 152 shares in the last quarter. Pegasus Asset Management Inc. increased its stake in Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after buying an additional 159 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC increased its stake in Edwards Lifesciences by 1.9% in the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after buying an additional 162 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on EW. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Piper Sandler increased their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Up 2.0 %

Shares of NYSE EW opened at $70.67 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $41.55 billion, a P/E ratio of 10.14, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a 50-day simple moving average of $71.68 and a two-hundred day simple moving average of $70.34.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,303 shares of company stock valued at $3,715,776 over the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.